LIAKOULI, Vasiliki
 Distribuzione geografica
Continente #
NA - Nord America 3.477
EU - Europa 2.080
AS - Asia 1.253
SA - Sud America 18
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 6
AF - Africa 3
Totale 6.848
Nazione #
US - Stati Uniti d'America 3.468
IE - Irlanda 692
CN - Cina 510
SG - Singapore 379
SE - Svezia 354
TR - Turchia 309
IT - Italia 262
DE - Germania 210
UA - Ucraina 193
GB - Regno Unito 147
FI - Finlandia 80
FR - Francia 79
BE - Belgio 31
IN - India 24
VN - Vietnam 20
BR - Brasile 16
CA - Canada 8
CZ - Repubblica Ceca 8
NL - Olanda 7
AU - Australia 6
EU - Europa 6
NZ - Nuova Zelanda 5
RU - Federazione Russa 5
CH - Svizzera 2
ID - Indonesia 2
IR - Iran 2
LU - Lussemburgo 2
ZA - Sudafrica 2
AR - Argentina 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
CO - Colombia 1
DK - Danimarca 1
ES - Italia 1
GE - Georgia 1
GR - Grecia 1
HK - Hong Kong 1
HU - Ungheria 1
JP - Giappone 1
LB - Libano 1
MD - Moldavia 1
MX - Messico 1
NO - Norvegia 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
TH - Thailandia 1
Totale 6.848
Città #
Jacksonville 775
Chandler 723
Dublin 692
Singapore 313
Boardman 230
Santa Clara 214
Izmir 201
Ann Arbor 135
Nanjing 121
New York 109
Lawrence 101
Princeton 101
Wilmington 100
San Mateo 93
Beijing 72
L'aquila 72
Ashburn 63
Woodbridge 51
Dearborn 49
Milan 44
Nanchang 43
Brussels 31
Shenyang 30
Mountain View 27
Seattle 26
Verona 26
Kunming 25
Jiaxing 23
Hebei 22
Dong Ket 20
Shanghai 20
Changsha 18
Helsinki 18
Des Moines 16
Los Angeles 16
Rome 15
Tianjin 15
L’Aquila 14
Jinan 13
Hefei 12
Zhengzhou 11
Dallas 9
Ningbo 9
Pune 9
Grafing 8
Guangzhou 7
Hangzhou 7
Munich 7
Norwalk 7
Pescara 7
Philadelphia 7
Bremen 6
Brno 6
Phoenix 6
Salerno 6
Lanzhou 5
Changchun 4
Edinburgh 4
Fremont 4
Houston 4
La Spezia 4
Redwood City 4
Taizhou 4
Auckland 3
Frankfurt am Main 3
Fuzhou 3
Jinhua 3
Melbourne 3
Naples 3
Redmond 3
Stockholm 3
Washington 3
Baotou 2
Bari 2
Belo Horizonte 2
Berlin 2
Busto Arsizio 2
Cedar Knolls 2
Chengdu 2
Frattamaggiore 2
Genzano di Roma 2
Kitzingen 2
London 2
Montreal 2
Mumbai 2
New Delhi 2
Olomouc 2
Orange 2
Paris 2
Rimini 2
Sant'Ambrogio di Valpolicella 2
Suzhou 2
Taranto 2
Xingtai 2
Alvorada 1
Amadora 1
Aquila 1
Ardebil 1
Athens 1
Auburn Hills 1
Totale 4.911
Nome #
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 118
Studio dell’espressione della chemochina SDF-1 e del suo recettore CXCR4 nella cute e nelle cellule endoteliali microvascolari di pazienti affetti da sclerosi sistemica (SSc). 109
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 105
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 103
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 101
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 98
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 98
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 98
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 97
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 97
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 94
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 94
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 93
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 87
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 86
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 86
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 85
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 83
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 83
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. 83
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 82
Cardiovascular disease in primary sjögren’s syndrome 81
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 80
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 80
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 80
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 79
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 78
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 78
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 78
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 77
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 77
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 76
SAT0489 Biologic Therapies and Infections in The Daily Practice: A Study on Historical Cohort from 3 Italian Rheumatologic Units 75
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. 75
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. 74
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 73
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 73
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 73
Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from Ssc Patients Induces an Anti Angiogenetic Effect, when Co-cultured with Endothelial Cells 72
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosi 72
FAS -670 gene promoter polymorphism confers susceptibility to systemic sclerosis 70
Interstitial lung disease in systemic sclerosis: current and future treatment. 70
SDF-1 expression in the skin of SSc patients. 69
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 69
Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications 68
Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28-. T cells in RA patients and correlation with atherosclerotic damage 68
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 68
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. 67
Variations of neuronal nitric oxide synthase in systemic sclerosis skin 66
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 66
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis 66
Methotrexate: an old new drug in autoimmune disease. 65
Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor 65
Caveolin-1 orchestrates vascular endothelial growth factor (VEGF) signaling control of angiogenesis during systemic sclerosis (SSC) 64
Cellular players in angiogenesis during the course of systemic sclerosis. 64
Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? 64
The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis 64
Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma. 63
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 63
Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis 62
Mesenchymal stem cells transplantation in Systemic Sclerosis: comment on the article by ATJ Maria et al 62
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 62
IMPAIREMENT OF ENDOTHELIAL DIFFERENTIATION FROM MESENCHYMAL STEM CELLS (MSC) IN SYSTEMIC SCLEROSIS (SSC): A NEW TOOL IN PATHOGENETIC MECHANISM 61
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. 61
Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. 60
Tocilizumab for the treatment of adult-onset Still's disease: Results from a case series 60
Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). 60
Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with sjogren’s syndrome 59
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 59
Senescent bone marrow mesenchymal stem cells (BM-MSCS) preserve their immune-regulatory effect on t cells during systemic sclerosis (SSC). 58
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 58
THE IL-33/ST2 PATHWAY IN SYSTEMIC SCLEROSIS 56
ASSOCIATION OF FAS-G670A GENE POLYMORPHISM WITH SYSTEMIC SCLEROSIS 56
Angiogenic cytokines and growth factors in systemic sclerosis. 56
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 56
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 56
CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS 55
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosis 54
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study 54
THU0582 Prognostic Factors of Macrophage Activation Syndrome in Adults: Analysis of 40 Cases in 2 Tertiary Referral Centers 54
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial 54
Pathogenesis of the endothelial damage and related factors. 53
Adipose stromal vascular fraction and regenerative therapy in SSc: Response to the article by Magalon et al 53
Differential expression of SDF-1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis: pathogenetic implication. 52
 Epidermal growth factor-like domain 7 (EGFL7) in skin of systemic sclerosis 52
The Vessels Contribute to Fibrosis in Systemic Sclerosis 52
VASCULAR SMOOTH MUSCLE CELLS (SMC) PROGENITORS: NEW PLAYERS IN SYSTEMIC SCLEROSIS (SSC) DEFECTIVE VESSEL REGENERATION. 49
Laboratory assessment in patients with suspected rheumatic musculoskeletal diseases: challenges, pitfalls and perspectives 49
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 49
Modificazioni della nitrossido-sintasi neuronale (nNOS) nella cute dei pazienti con sclerosi sistemica (SSc). 48
Endothelial Progenitor Cells (EPC) characterization in systemic sclerosis (SSc) patients 47
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 46
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis 45
THE OCCURRENCE OF SUBCLINICAL AND CLINICAL ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS, RESULTS FROM THE 3-YEAR, MULTICENTER, PROSPECTIVE, OBSERVATIONAL, GIRRCS STUDY 44
Interstitial lung disease in systemic sclerosis: Pathophysiology and therapy 44
DIFFERENTIAL EXPRESSION OF SDF-1 AND ITS RECEPTOR CXCR4 IN THE SKIN AND ENDOTHELIAL CELLS OF SYSTEMIC SCLEROSIS PATIENTS: PATHOGENETIC IMPLICATION 43
null 43
Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 42
FRI0414 Evaluation of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of systemic sclerosis 40
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6 38
Totale 6.852
Categoria #
all - tutte 29.789
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.789


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020636 0 0 0 0 0 149 150 18 111 45 11 152
2020/2021927 22 106 16 123 110 39 123 7 105 45 171 60
2021/2022637 42 36 162 53 13 10 9 27 44 35 47 159
2022/20232.035 153 127 32 238 160 215 4 118 882 15 63 28
2023/2024484 71 35 28 51 50 158 10 25 1 22 9 24
2024/2025815 39 38 187 62 339 150 0 0 0 0 0 0
Totale 7.001